161 related articles for article (PubMed ID: 38462607)
1. Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review.
Li X; Yan F
Cancer Imaging; 2024 Mar; 24(1):35. PubMed ID: 38462607
[TBL] [Abstract][Full Text] [Related]
2. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
[TBL] [Abstract][Full Text] [Related]
3. Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients: use of MRI radiomics data from three regions with multiple machine learning algorithms.
Zheng G; Peng J; Shu Z; Jin H; Han L; Yuan Z; Qin X; Hou J; He X; Gong X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):147. PubMed ID: 38512406
[TBL] [Abstract][Full Text] [Related]
4. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
5. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
6. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
[TBL] [Abstract][Full Text] [Related]
7. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
[TBL] [Abstract][Full Text] [Related]
8. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
[TBL] [Abstract][Full Text] [Related]
9. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
[TBL] [Abstract][Full Text] [Related]
10. Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.
Rella R; Contegiacomo A; Bufi E; Mercogliano S; Belli P; Manfredi R
Br J Radiol; 2021 Mar; 94(1119):20200630. PubMed ID: 33035073
[TBL] [Abstract][Full Text] [Related]
11. A clinicopathological-imaging nomogram for the prediction of pathological complete response in breast cancer cases administered neoadjuvant therapy.
Yang W; Yang Y; Zhang C; Yin Q; Zhang N
Magn Reson Imaging; 2024 Sep; 111():120-130. PubMed ID: 38703971
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging.
Schrading S; Kuhl CK
Radiology; 2015 Dec; 277(3):687-96. PubMed ID: 26176656
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
Nguyen AA; Arasu VA; Strand F; Li W; Onishi N; Gibbs J; Jones EF; Joe BN; Esserman LJ; Newitt DC; Hylton NM
Tomography; 2020 Jun; 6(2):101-110. PubMed ID: 32548286
[TBL] [Abstract][Full Text] [Related]
14. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
15. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
[TBL] [Abstract][Full Text] [Related]
16. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
[TBL] [Abstract][Full Text] [Related]
17. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
Chen JH; Yu H; Lin M; Mehta RS; Su MY
Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of background parenchymal enhancement on breast MRI: a systematic review.
Bignotti B; Signori A; Valdora F; Rossi F; Calabrese M; Durando M; Mariscotto G; Tagliafico A
Br J Radiol; 2017 Feb; 90(1070):20160542. PubMed ID: 27925480
[TBL] [Abstract][Full Text] [Related]
19. Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
Liang X; Yu X; Gao T
Eur J Radiol; 2022 May; 150():110247. PubMed ID: 35290910
[TBL] [Abstract][Full Text] [Related]
20. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]